It is very uncertain whether vaginal misoprostol changes blood loss: haemoglobin difference > 10 g/L compared with placebo (very low certainty).
It is very uncertain whether vaginal misoprostol changes pain (opiate use) compared with placebo (very low certainty).
Vaginal misoprostol showed no clear difference in woman’s satisfaction/acceptability of method compared with placebo (low certainty).
Vaginal misoprostol may leads to lower complete miscarriage compared with surgical evacuation of uterus (low certainty).
Vaginal misoprostol showed no clear difference in pelvic infection compared with surgical evacuation of uterus (low certainty).
Taxane‐containing chemotherapy leads to lower overall survival compared with any chemotherapy without taxane (high certainty).
Taxane‐containing chemotherapy leads to lower disease‐free progression compared with any chemotherapy without taxane (high certainty).
Taxane‐containing chemotherapy showed no clear difference in febrile neutropenia compared with any chemotherapy without taxane (moderate certainty).
Taxane‐containing chemotherapy probably leads to higher neuropathy (including grade 3/4 sensory or motor neuropathy, or both) compared with any chemotherapy without taxane (moderate certainty).
Taxane‐containing chemotherapy showed no clear difference in cardiotoxicity (including grade 3/4 and congestive cardiac failure) compared with any chemotherapy without taxane (moderate certainty).
The review found no eligible studies for this question.
It is very uncertain whether peripartum/postnatal prophylaxis: UFH changes symptomatic thromboembolic events ( compared with no treatment (very low certainty).
It is very uncertain whether peripartum/postnatal prophylaxis: UFH changes symptomatic PE ( compared with no treatment (very low certainty).
It is very uncertain whether peripartum/postnatal prophylaxis: UFH changes symptomatic DVT ( compared with no treatment (very low certainty).
It is very uncertain whether peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) changes symptomatic thromboembolic events (timing of assessment unclear,… compared with no treatment/placebo (very low certainty).
It is very uncertain whether peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) changes symptomatic PE (timing of assessment unclear, within 6 weeks… compared with no treatment/placebo (very low certainty).
It is very uncertain whether surgery for Bell's palsy changes complete recovery of facial nerve function at 12 months Defined as:… compared with medical treatment (oral prednisolone) or no treatment (very low certainty).